American Society of Hirudotherapy

Neuromacin

Macin-family antimicrobial protein with reported neuronal-tissue specificity — leech innate immunity component.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Neuromacin6.5 kDa
Molecular weight (kilodaltons) of Neuromacin (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Aeromonas infection

Clinical translation limit

Neuromacin's in vitro antimicrobial activity does NOT establish clinical efficacy. No FDA-approved derivative exists. The macin family remains a preclinical innate-immunity research target.

Molecular Profile

Category
Antimicrobial
Evidence tier
Preclinical
Molecular weight
6,500 Da
Source species
Hirudo medicinalis
Discovered
2008

Biological Targets

  • → bacterial membranes (Gram-positive emphasis)

Key Citations

  1. Jung S et al. (2012), J Biol Chem · PMID 22396551

External Resources

    Related Antimicrobial Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.